医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Research and Markets: Lifecycle Management Strategies: Pharma-Payer Deals – Creative agreements are used at different stages of the brand lifecycle to maximize sales

2012年09月26日 AM02:12
このエントリーをはてなブックマークに追加


 

DUBLIN

Research and Markets (http://www.researchandmarkets.com/research/26rzgm/lifecycle) has announced the addition of the “Lifecycle Management Strategies: Pharma-Payer Deals – Creative agreements are used at different stages of the brand lifecycle to maximize sales” report to their offering.

With increasing cost-containment measures, payers have emerged as the key decision-making group, as proving the economic and clinical value of a drug is of central importance in achieving commercial success. As a result, pharma-payer deals have been used not only for launch products but also for mature brands in order to drive market share in the face of branded and generic competition alike.Analysis of success drivers and resistors of pharma-payer deals as a lifecycle management strategy. Discussion of how pharma-payer deals can satisfy key stakeholder needs.

Case study of recent successful and unsuccessful pharma-payer deals. Risk-sharing agreements are based on a “guaranteed” outcome resulting from the treatment, be that based on financial or outcome/performance criteria. If the outcome is achieved the payer will pay; if not, the pharmaceutical company refunds the payer for the cost of the drug. Risk-sharing agreements have the potential to reconcile the needs of different stakeholders: pharma companies secure market entry, the payer is financially protected from patients who fail to respond to drug treatment, and patients gain access to innovative therapies.

While straightforward discount and rebate deals are usually used to maintain sales later in the lifecycle when the drug in question is facing greater competition, recently, creative risk-sharing deals have also been used for mature brands in order to drive market share in the face of branded and generic competition alike. How can pharma-payer deals drive or maintain franchise sales? How can pharma-payer deals be used at different stages of a brand’s lifecycle? In which markets are pharma-payer deals commonly used?

Key Topics Covered:

– EXECUTIVE SUMMARY

– PHARMA-PAYER DEALS OVERVIEW

– PHARMA-PAYER DEALS CASE STUDIES

– BIBLIOGRAPHY

– APPENDIX

– TABLES

– FIGURES

Companies Mentioned

– Hutchison 3G UK Limited,

– Janssen Pharmaceuticals, Inc.

For more information visit http://www.researchandmarkets.com/research/26rzgm/lifecycle

CONTACT

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • CANbridge Life Sciences Receives Approval to Commence CAN017 Ib/III Trial in Esophageal Squamous Cell Cancer (ESCC) In China
  • AVEO Announces Acceptance of CANbridge Investigational New Drug Application for CAN017 (AV-203) Trial in Esophageal Squamous Cell Cancer (ESCC) in China
  • STAAR Surgical and Shinjuku LASIK Clinic in Japan Announce Strategic Cooperation Agreement
  • 新研究调查诊断性多通道睡眠检查之前采用Masimo SET®脉搏氧饱和度仪居家监测筛查唐氏综合征患儿罹患阻塞性睡眠呼吸暂停的风险
  • ダウン症候群の小児を対象とする睡眠時障害診断のマルチチャンネル研究に先立つ閉塞性睡眠時無呼吸症リスクのスクリーニングとしてMasimo SET®パルスオキシメトリーを使用するホームモニタリングの有用性を検討する新研究